Augmentation of tumor immunity in mice by intralesional injection of vitamin A

Biological and Pharmaceutical Bulletin

Volumn 21, Issue 4, 1998, Pages 339-345

  Kashida, Tatsuo ^a   Narasaki, Naoko ^a   Yano, Toshiro ^a   Tsuzurahara, Kei ^a   Takeyama, Shigeyuki ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Double grafted tumor system; Intralesional injection; Retinoid receptor; Tumor immunity; Vitamin A

Indexed keywords

RETINOID RECEPTOR; RETINOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; IMMUNITY; INTRALESIONAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; SPLEEN CELL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 0031968310     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.21.339     Document Type: Article

References (53)

1. Sporn M. B., Dunlop N. M., Newton D. L., Smith J., Fed. Proc., 35, 1332-1338 (1976).
2. Moon R. C., McCormick D. L., Mehta R. G., Cancer Res., 43 (Suppl.), 2469s-2475s (1983).
3. Sporn M., Roberts A., Cancer Res., 43, 3034-3040 (1983).
4. Moon R. C., Itri L. M., "Retinoids and Cancer," Vol. 2, ed. by Sporn M. B., Roberts A. B., Goodman D. S., The Retinoids. Orlando, FL: Academic Press, Inc., 1984, pp. 327-371.
5. Bollag W., Lancet 1, 860-863 (1983).
6. Smith M. A., Parkinson D. R., Cheson B. D., Friedman M. A., J. Clin. Oncol., 10, 839-864 (1992).
7. Lippman S. M., Kessler J. F., Meyskons F. L., Jr., Cancer Treat. Rep., 71, 391-405 (1987).
8. Aapro M. S., Eur. J. Cancer, 31A, 834-835 (1995).
9. Lotan R., Biochem. Biophys. Acta, 605, 33-91 (1980).
10. Wolf G., Physiol. Rev., 64, 873-937 (1984).
11. Leid M., Kastner P., Chambon P., Trends Biochem. Sci., 17, 427-433 (1992).
12. Malkovsky M., Medawar P. B., Immunology Today, 5, 178-180 (1984).
13. Dillehay D. L., Shealy Y. F., Lamon E. W., Cancer Res., 49, 44-50 (1989).
14. Eccles S. A., Barnett S. C., Alexander P., Cancer Immunol. Immunother., 19, 109-114 (1985).
15. Eccles S. A., Purvies H. P., Barnett S. C., Alexander P., Cancer Immunol. Immunother., 19, 115-120 (1985).
16. Forni G., Sola S. C., Giovarelli M., Santoni A., Martinetto P., Vietti D., J. Natl. Cancer Inst., 76, 527-533 (1986).
17. Felix E. L., Lloyd B., Cohen M. H., Science, 189, 886-888 (1975).
18. Dennert G., Crowley C., Kouba J., Lotan R., J. Natl. Cancer Inst., 62, 89-94 (1979).
19. Malkovsky M., Dore C. Hunt R., Palmer L., Chandler P., Medawar P. B., Proc. Natl. Acad. Sci. U.S.A., 80, 6322-6326 (1983).
20. Tomita Y., Himeno K., Nomoto K., Endo H., Hirohata T., Experientia, 41, 92-93 (1985).
21. Jiang X. L., Dillehay D. L., Everson M. P., Tilden A. B., Lamon E. W., Int. J. Immunopharmacol., 14, 195-204 (1992).
22. Schleicher R. L., Moon R. C., Patel M. K., Beattie C. W., Cancer Res., 48, 1465-1469 (1988).
23. Halter S. A., Winnier A. R., Arteaga C. L., J. Cell. Physiol., 156, 80-87 (1993).
24. Nunes I., Kojima S., Rifken D., Cancer Res., 56, 495-499 (1996).
25. Lotan R., Francis G. K., Freeman C., Waxman S., Cancer Res., 50, 3453-3464 (1990).
26. Zorn N. E., Sauro M. D., Int. J. Immunopharmacol., 17, 303-311 (1995).
27. Breitman T. R., Selonick S. E., Collins S. J., Proc. Natl. Acad. Sci. U.S.A., 77, 2936-2940 (1980).
28. McBurney M. W., Costa S., Pratt M. A. C., Cancer Invest., 11, 590-598 (1993).
29. Lotan R., Cancer Res., 54, 1987s-1990s (1994).
30. Lin T. H., Chu T. M., J. Biol. Chem., 267, 1335-1339 (1992).
31. Eccles S. A., Biochem. Pharmacol., 34, 1599-1610 (1985).
32. Lin T. H., Chu T. M., Cancer Res., 50, 3013-3018 (1990).
33. Rumore M. M., Clin. Pharm., 12, 506-514 (1993).
34. Kashida T., Narasaki N., Sakai A., Tsujihara K., Tsuzurahara K., Takeyama S., Biol. Pharm. Bull., 18, 1492-1497 (1995).
35. Kagechika H., Kawachi E., Hashimoto Y. Himi T., Shudo K., J. Med. Chem., 31, 2182-2192 (1988).
36. Ebina T., Murata K., Jpn. J. Cancer Res. (Gann), 82, 1292-1298 (1991).
37. Winn H. G., J. Immunol., 86, 228-239 (1961).
38. Kashida T., Narasaki N., Tsujihara K., Naito K., Takeyama S., Int. J. Immunopharmacol., 18, 311-319 (1996).
39. Cottney J., Bruin J., Lewis J. A., Agents Actions, 10, 48-56 (1980).
40. Shudo K., Kagechika H., Adv. Drug Res., 24, 81-119 (1993).
41. Kasai M., Yoneda T., Habu S., Maruyama Y., Okumura K., Tokunaga T., Nature (London), 291, 334-338 (1981).
42. Debrick J. E., Campbell P. A., Staerz U. D., J. Immunol., 147, 2846-2851 (1991).
43. Borsos T., Bast R. C., Jr., Ohanian S. H., Segerling M., Zbar B., Rapp H. J., Ann. N.Y. Acad. Sci., 276, 565-571 (1976).
44. Zbar B., Tanaka T., Science, 172, 271-273 (1971).
45. Felix E. L. Cohen M. H., Loyd B. C., J. Surg. Res., 21, 307-312 (1976).
46. Levine N., J. Invest. Dermatol., 85, 89-92 (1985).
47. Athanassiades T. J., J. Natl. Cancer Inst., 67, 1153-1156 (1981).
48. Berd D. S., Hammond W. G., Pilch Y. H., Cancer Res., 29, 1379-1384 (1969).
49. Taub R. N., Drantz A. R., Dresser D. W., Immunology, 18, 171-186 (1970).
50. Fisher B., Saffer E. A., Fisher E. R., Proc. Soc. Exp. Biol. Med., 135, 68-71 (1970).
51. Hashimoto Y., Kagechika H., Kawachi E., Shudo K., Jpn. J. Cancer Res. (Gann), 79, 473-483 (1988).
52. Eyrolles L., Kagechika H., Kawachi K., Fukasawa H., Iijima T., Matsushima Y., Hashimoto Y., Shudo K., J. Med. Chem., 37, 1508-1517 (1994).
53. Umemiya H., Kawachi E., Kagechika H., Fukasawa H., Hashimoto Y., Shudo K., Chem. Pharm. Bull., 43, 1827-1829 (1995).